Haghiac Maricela, Basu Subhabrata, Presley Larraine, Serre David, Catalano Patrick M, Hauguel-de Mouzon Sylvie
Center of Reproductive Health, Metrohealth Medical Center (M.H., S.B., L.P., D.S., P.M.C., S.H.M.), Case Western Reserve University, Cleveland, Ohio 44106; and Genomic Medicine Institute (D.S.), Cleveland Clinic Lerner Research Institute, Cleveland, Ohio 44195.
J Clin Endocrinol Metab. 2014 Sep;99(9):3427-34. doi: 10.1210/jc.2013-4074. Epub 2014 May 5.
Adiponectin (adpN) production is down-regulated in several situations associated with insulin resistance. The hypoadiponectinemia, which develops in late pregnancy, suggests a role of adpN in pregnancy-induced insulin resistance.
In obese pregnancy there is a decreased systemic adpN, which results from down-regulation of gene expression in adipose tissue.
One hundred and thirty-three women with uncomplicated pregnancies and a wide range in pre-gravid body mass index (18-62 kg/m(2)) were recruited at term for a scheduled cesarean delivery. Maternal blood, placenta, and sc abdominal adipose tissue were obtained in the fasting state. DNA methylation was analyzed by MBD-based genome-wide methylation sequencing and methyl-specific PCR of placenta and maternal adipose tissue. mRNA and protein expression were characterized by real-time RT-PCR and immunodetection. Plasma adpN, leptin, and insulin were assayed by ELISA.
Maternal adipose tissue was the prominent site of adpN gene expression with no detectable mRNA or protein in placenta. In obese women, adipose tissue adpN mRNA was significantly decreased (P < .01) whereas DNA methylation was significantly increased (P < .001) compared with lean women. The decreased adipose tissue expression resulted in normal-weight women having significantly greater plasma adpN compared with the severely obese (12.8 ± 4.3 ng/mL vs 8.6 ± 3.1, P < .001). Plasma adpN was negatively correlated with maternal body mass index (r = -0.28, P < .001) and homeostasis model assessment indices of insulin sensitivity (r = -0.32, P < .001) but not with gestational weight gain.
Maternal adipose tissue is the primary source of circulating adpN during pregnancy. Further, based on our results, the placenta does not synthesize adiponectin at term. Obesity in pregnancy is associated with negative regulation of adpN adipose expression with increase in adpN DNA methylation associated with lower mRNA concentrations and hypoadiponectinemia. Maternal hypoadiponectinemia may have functional consequences in down-regulating biological signals transmitted by adpN receptors in various tissues, including the placenta.
脂联素(adpN)的产生在几种与胰岛素抵抗相关的情况下会下调。妊娠晚期出现的低脂联素血症表明adpN在妊娠诱导的胰岛素抵抗中起作用。
在肥胖妊娠中,全身adpN减少,这是由脂肪组织中基因表达下调导致的。
招募了133名妊娠情况正常、孕前体重指数范围广泛(18 - 62 kg/m²)的女性,在足月时进行择期剖宫产。在空腹状态下获取母体血液、胎盘和腹部皮下脂肪组织。通过基于MBD的全基因组甲基化测序以及胎盘和母体脂肪组织的甲基化特异性PCR分析DNA甲基化。通过实时RT-PCR和免疫检测来表征mRNA和蛋白质表达。采用ELISA法检测血浆中的adpN、瘦素和胰岛素。
母体脂肪组织是adpN基因表达的主要部位,胎盘中未检测到mRNA或蛋白质。与瘦女性相比,肥胖女性的脂肪组织adpN mRNA显著降低(P < 0.01),而DNA甲基化显著增加(P < 0.001)。脂肪组织表达的降低导致正常体重女性的血浆adpN显著高于重度肥胖女性(12.8 ± 4.3 ng/mL对8.6 ± 3.1,P < 0.001)。血浆adpN与母体体重指数呈负相关(r = -0.28,P < 0.001),与胰岛素敏感性的稳态模型评估指数呈负相关(r = -0.32,P < 0.001),但与孕期体重增加无关。
孕期母体脂肪组织是循环中adpN的主要来源。此外,根据我们的结果,足月胎盘不合成脂联素。妊娠肥胖与adpN脂肪表达的负调控相关,adpN DNA甲基化增加与mRNA浓度降低和低脂联素血症有关。母体低脂联素血症可能会对下调包括胎盘在内的各种组织中adpN受体传递的生物信号产生功能性影响。